Skip to content
lsd.com
CompletedPhase 1

A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males

NCT02935725 · Autifony Therapeutics Limited

Closed to entry
Status
Not accepting participants
Phase 1
Phase
22
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

A Phase 1, Single-centre, Double-blind, Placebo controlled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Significant difference in BOLD phMRI signals after dosing with AUT00206 vs placebo

    Measured over 15 Weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 45 Years
Ages
MALE
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * Male aged 18 to 45 years, inclusive at Visit 1. * Healthy on the basis of medical history, psychiatric history, physical examination, vital signs, 12-lead electrocardiogram (ECG), haematology, blood chemistry and urinalysis within 6 weeks of Visit 2. * Right-handed. * Not a regular smoker (maximum 5 cigarettes per week or equivalent). Exclusion Criteria: * History of, or current condition of, migraine headaches or has undergone operations to the head. * History of significant claustrophobia.

Where

1 study site

FacilityCityRegionCountry
University Of ManchesterLondon—United Kingdom

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT02935725 on ClinicalTrials.gov →

Last updated in the registry 2017-11-27. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Indication